The Combined Effect of Dichloroacetate and 3-Bromopyruvate in Colorectal Cancer Cell Line, HT-29; The Mitochondrial Pathway Apoptosis

doi:10.21203/rs.3.rs-415317/v1

Download PDF

Research Article

The Combined Effect of Dichloroacetate and 3-Bromopyruvate in Colorectal Cancer Cell Line, HT-29; The Mitochondrial Pathway Apoptosis

https://doi.org/10.21203/rs.3.rs-415317/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 07 Aug, 2021

Read the published version in BMC Cancer →

You are reading this latest preprint version

Background

5-Fluorouracil (5-FU) is regarded as the first line treatment for colorectal cancer; however, its effectiveness is limited by drug resistance. The ultimate goal of cancer therapy is induction of cancer cell death to achieve an effective outcome with minimal side effects. The present work aimed to assess the anti-cancer activities of mitocans which can be considered as an effective anticancer drug due to high specificity in targeting cancer cells.

Methods

MTT (3–4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide) assay was performed to determine the effects of our mitocans on cell viability and cell death. Apoptosis and necrosis, caspase 3 activity, mitochondrial membrane potential and ROS production in HT29 cell lines were analyzed by ApopNexin™ FITC/PI Kit, Caspase- 3 Assay Kit, MitoTracker Green and DCFH-DA, respectively. Moreover, quantitative real-time polymerase chain reaction (qRT-PCR) was performed to detect the expression level of pro-apoptotic (Bax) and anti-apoptotic (Bcl-2) genes in HT29 cell lines.

Results

treatment with mitocans (3Br-P + DCA) inhibited the growth of HT29. Moreover, 3Br-P + DCA significantly induced apoptosis and necrosis, activation of caspase 3 activity, depolarize the mitochondrial membrane potential, and ROS production. At a molecular level, 3Br-P + DCA treatment remarkably down-regulated the expression of Bcl-2, while up-regulated the expression of Bax.

Conclusion

mitocans, in particular the combined drug, 3Br-P + DCA, could be regarded and more evaluated as a safe and effective compound for CRC treatment. Targeting hexokinase and pyruvate dehydrogenase kinase enzymes may be an option to overcome 5-FU -mediated chemo-resistant in colorectal cancer.

Cancer Biology

Oncology

Apoptosis

3-Bromopyruvate

Dichloroacetate

Colorectal cancer cells

5-Fluorouracil

Cancer, a pathology characterized by unchecked division of cells, is one of the fatal diseases with an increasing number of cases all over the world (1). Malignant neoplasms with the source of the intestine, rectum and anal canal, classified as colorectal cancer (CRC), are the third and second leading causes of death in males and females in the world, respectively (2). Approximately, up to 1.8 million new cases of CRC were reported to occur yearly in the world, with an estimated 881000 cases dying of this malignancy (3). Despite substantial progresses in CRC screening measures and treatment, the prognosis of patients with this cancer remains poor, demanding novel therapeutic strategies to manage the disease (4). In this respect, 5-Fluorouracil (5-FU) is a well-known anti-cancer drug commonly used to treat CRC; the agent interferes with DNA and RNA to disrupt the metabolism of the uracil, which lead to the breakdown of DNA and apoptosis of the cancer cells. Nonetheless, it is reported that the resistance to 5-FU during the course of CRC treatment plays a major role in treatment failure (5–7). Therefore, the expansion and development of new and more effective drug combinations for CRC treatment is guaranteed. Studies show that some anti-cancer agents, known as mitocans, which exert their anti-tumor activities by modulating mitochondria, can be considered as an effective anti-cancer drug due to high specificity in targeting cancer cells (8). Dichloroacetate (DCA) and 3-bromopyruvate (3Br-P) are two such anti-tumor agents, which belong to class 1 (hexokinase inhibitors) and class 7 (Krebs cycle inhibitors) of mitocans, respectively (8). DCA activates pyruvate dehydrogenase by inhibiting the pyruvate dehydrogenase kinase enzyme, which ultimately boosts the production of Acetyl-CoA, as a precursor of the Krebs cycle. The enhancement of the Krebs’ cycle activity in turn increases the activity of the electron transfer chain; a function that increases the production of reactive oxygen species with mitochondrial origin, which lead to selective killing of cancer cells (9). The another agent, 3Br-P, acts as a potent inhibitor of hexokinase; an enzyme that is overexpressed in cancer cells and is essential for the metabolism of cancer cells. The enzyme binds to voltage-dependent anion channel (VDAC, or porin) in the outer mitochondrial membrane, which results in resistance to chemotherapy by inhibiting glycolysis (10). Recent studies reported that multi-target therapy acts more effective than single-target one (11). Numerous studies have shown a synergistic action of DCA or 3Br-P with other compounds (12)(13). However, the present work assessed the anticancer effects of 3Br-P in combined with DCA in a colorectal cancer cell line, HT-29.

Human colorectal adenocarcinoma (HT-29) and human embryonic kidney 293 (HEK-293) cell lines were purchased from Iranian Biological Resource Center (Tehran, Iran). The anti-cancer agents, 5-FU and DCA/3Br-P, were supplied by Ebewe Pharma company and Sigma Aldrich (Saint Louis, MO), respectively. Dulbecco's modified eagle's medium (DMEM), fetal bovine serum (FBS), phosphate-buffered saline (PBS), and antibiotic (penicillin-streptomycin) were purchased from Invitrogen Co, (Carlsbad, CA). Furthermore, MTT (3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide), 2,7-dichlorofluorescein diacetate (DCFH-DA), Annexin V/FITC apoptosis detection kit and MitoTracker Green supplied by Sigma Aldrich (Saint Louis, MO) were applied in this work. Moreover, Caspase 3 Assay kit, Bax, Bcl-2, and GAPDH primers were obtained from Qiagen (Hilden, Germany).

Cell culture and treatment

The cell lines, HT29 and HEK-293, were cultured in DMEM media with 10% FBS at 37°C, under a humidified atmosphere with 5% CO2.

Cell counting

The trypan blue exclusion dye assay was applied to determine the number of living cells in a cell suspension. Shortly, 20 μl of trypan blue dye 0.4% was added and mixed with equal parts of cell suspension in a micro tube. Subsequently, one side of a hemacytometer counter was filled with the cell suspension by placing the tip of the pipette at the notch, followed by counting the cells on the stage of a light microscope. The Calculation of cell percentage per milliliter was done via the following formula: cells/ml = average count per square × dilution factor × 10⁴. Moreover, the experiments were performed at least for three times (14).

Cytotoxicity assays

Briefly, the HT-29 and HEK-293 cells were grown in 96-well plate (5000cells/well) in 100µl medium and left overnight to adhere. Then, cells were treated with different concentrations of 3Br-P, DCA and 5-FU alone and combined with together, and incubate in media containing 10% FBS at 37°C and 5 - 6.5% CO2 for 48 hours. After treatment, 10 μl of the MTT (5 mg/ml in PBS) was added to each well and incubated for 3.5 hours in 37 °C. Subsequently, the medium was removed and the formazan crystals were solubilized in 150µl of DMSO. Plates were covered with foil and shacked on an orbital shaker for 15 minutes, and in the final step complete solubilization of the purple formazan crystals and reduced MTT were measured spectrophotometrically by microplate enzyme-linked immunosorbent assay (ELISA) reader at 570 nm according to the filters available for the ELISA reader. Viability inhibition was calculated as follows: cell viability (%) = Ab (test) /Ab (control) ×100 (15).

Measurement of apoptosis and necrosis

This was measured according to ApopNexin™ FITC/PI Kit instructions. In summary, 1.5×10⁵ cells were seeded and treated with different concentrations of 3Br-P, DCA and 5-FU alone and combined together in HT-29 cells for 48 hours. After drug exposure, the cells were harvested, and then were washed with ice-cold PBS and stained with ApopNexin^TM FITC kit for 15 minutes at room temperature in the dark. Stained samples were analyzed by Galaxy flow cytometer (ser. No: 0105362) (16).

Caspase 3 Assay

Caspase 3 activity was determined via using the specific caspase-3 substrate, prepared by Caspase- 3 Assay Kit, Colorimetric Qiagen (Hilden, Germany). In short, after treating the cells with 3Br-P, DCA and 5-FU alone and/or combined together, the caspase-3 activity was measured by ELISA at 504 nm, according to the protocol of the kit (17).

Mitochondrial membrane potential (ΔΨm)

MitoTracker Green is a fluorescent color that selectively attaches covalently to mitochondrial proteins in the mitochondrial matrix by reacting with free thiol groups of cysteine roots. Briefly, in each well of 24-well plates, about 10⁵cells were seeded and incubated overnight, and subsequently treated with 3Br-P, DCA and 5-FU alone and/or combined together for 48 hours. Then, the cells were harvested and incubated with 10 µl of MitoTracker Green for 30 minutes at 37°C in a 5% CO2 incubator. After incubation, the samples were placed on ice and immediately were assessed by flow cytometry (18).

Determination of ROS production

To perform this, 24-well plates were seeded with 10⁵ cells in a complete culture medium and allowed to adhere overnight. In all wells (90% confluence) treated with 3Br-P, DCA and 5-FU alone and/or combined together, cells were washed twice with PBS, followed by staining with 10 µM DCFH-DA for 45 min. Then, after 2, 4, 8, and 12 hours, the formation of fluorescent-oxidized DCF was measured by fluorimetry (535 nm excitation and 635 nm emission) (19).

RT-PCR and qPCR reaction

Total RNA was isolated according to the manufacturer's instructions supplied by Rneasy Mini Kit (QIAgEN-cat. No. 74106.). Afterwards, cDNA was synthesized from 2μg of the total RNA using the Prime Script RT-PCR kit (Quanti Tect Rev. Transcription Kit), according to the manufacturer's instructions. Quantitative real-time PCR (qPCR) assays were performed with Roche LightCycler in 96-wells Gene Discs, using a final reaction volume of 20 µL containing 0.4µl of each forward and reverse primers (with concentration of 10 µmol/L) (Table 1), 2x SYBR Green master mix (as indicated in the results section) and <1ng/µl of cDNA samples. The following thermal profile was applied; the cycling conditions used were as follows: 95 °C for 15 min; 30 cycles of 95 °C for 15 s, 66 °C for 30 Sec. Melting curve analysis was performed by ramping the temperature from 60 °C to 90 °C. All reactions were conducted in triplicate. The fold change of gene expression was calculated using 2^−ΔΔCt after normalizing to the expression level of GAPDH.

Statistical analysis

All experiments were performed at least through 3 trials. All quantitative data are expressed as mean ± SD. One-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons were executed for comparison of different parameters between the groups using a GraphPad Prism 5 software (GraphPad Prism, San Diego, California, The U.S.A.).

In vitro cytotoxicity

In the present study, cytotoxicity was assessed in the different cell lines by using MTT assay. The IC50 values for the CRC cell line obtained from the study are reported as follows: 5-FU;25µM, 3Br-P;120µM, DCA;120mM, 5-FU+3Br-P;12.5µM+80µM, 5-FU+DCA;12.5µM+80mM, 3Br-P+DCA; 60µM+60mM. Nonetheless, in the normal cell line, HEK-293, the above mentioned doses had no significant effects at 48 hours after treatment (Figure 1).

In vitro ROS activity

The ROS activity in the treated group was shown to be significantly higher than the untreated ones, at the times of 2, 4 and 8 hours after treatment. Furthermore, among the mentioned times in the treated group, the ROS amount was found to be higher during 4 hours after treatment. Moreover, the combinations of 5-FU+3Br-P and 3Br-P+DCA in the treated HT-29 cells produced more ROS amount than the other compounds (Figure 2).

In vitro assessment of mitochondrial membrane potential (ΔΨm)

Based on our results, the compound 3Br-P significantly promoted ΔΨm reduction in HT-29 cells in comparison with the negative control and other treated groups. These results show that the combined agents, including 5-FU+3Br-P, 5-FU+ DCA, and 3Br-P+DCA significantly increased ΔΨm decrease in HT-29 cells in compared to the negative control (Figure 3, 4, and 5).

Caspase 3 assay

Treatment of the HT-29 cells with all the assessed compounds (5-FU, 3Br-P, DCA, 5-FU+ DCA, 5-FU+3Br-P, and 3Br-P+DCA) significantly increased the caspase 3 activity in compared to untreated cells (p≤ 0.05) (Figure 6).

Quantification of the Bax/Bcl-2 ratio

Treatment of the HT-29 cells with 5-FU, 3Br-P, DCA, 5-FU+DCA, 5-FU+3Br-P, and 3Br-P+DCA significantly increased the Bax/Bcl-2 genes expression in compared to the control ones (p≤ 0.05). Interestingly, there was no a significant difference of the Bax/Bcl-2 gene expression between HT-29 cells treated with 5-FU alone and those treated by 3Br-P+DCA (Figure 7).

Induction of apoptosis and necrosis by flow cytometry

Annexin-V FITC/PI staining confirmed that 5-FU, 3Br-P, DCA, 5-FU+DCA, 5-FU+3Br-P, and 3Br-P+DCA could induce apoptosis in HT-29 cells. All the treated HT-29 cells had a significant higher necrotic pattern as compared to untreated cells (p≤ 0.05). It was found that the treatment with 5-FU significantly increases the percentage of apoptosis from 0.465% in the control cells to 32.35% in the treating cells. Moreover, the 5-FU+DCA, 5-FU+3Br-P, and 3Br-P+DCA groups had a significantly increased apoptosis in compared to the control, 3Br-P and DCA groups (Figure 8, 9 and 10).

Globally, CRC is the second and third leading causes of death in women and men, respectively (20). The aim of cancer therapy is to inhibit proliferation (cytostatic effects) and to induce cell death (cytotoxic effects) of cancer cells (21), to achieve an effective outcome with minimal side effects (23). In most cancers, the first therapeutic strategy used to treat is surgical removal. Obviously, surgery for some types of cancers is relatively simple and for other types is impractical (22). Therefore, chemotherapy and radiotherapy are used to control or eradicate metastatic cells. Traditional chemotherapy is the use of drugs to target the cell cycle, DNA, RNA, and proteins in cancer cells. 5-FU is the first traditional chemotherapy and the first choice for CRC therapy, whose effectiveness is limited by drug resistance (23). Mitochondria have emerged as an attractive target for anticancer drugs, so that the compounds such as mitocans that target mitochondria with anti-cancer activity has become a focus of recent research due to their great clinical potential (24)(25). In our study, we have described the cytotoxic effect of the mitochondria-targeted drugs, 3Br-P + DCA, in HT-29 cell line and assessed the mechanism of its action. Recent studies have shown that therapies having multiple targets result in greater benefits than single-targeted therapies (26). There are several studies suggesting a synergistic action of 3Br-P or DCA with other compounds. For instance, the selective inhibitor of glycolytic enzymes, 3Br-P, when combined with sodium citrate (SCT), resulted in reduced ATP level, induced mitochondrial-mediated apoptosis, and suppressed tumor growth in gastric cancer cells (27). In the same way, when cisplatin or oxaliplatin combined with 3Br-P, amazingly boosted the antiproliferative effects of the platinum drugs in HCT116 cells (28). Moreover, antitumor effects of tamoxifen, the first-line adjuvant endocrine therapy for estrogen receptor-positive breast cancer, were markedly improved when used with 3Br-P, as a sensitizer to target glycolysis (29). On the other hand, in colorectal cancer cells parallel results were obtained using traditional chemotherapy drugs with DCA. Ayyanathan et al. demonstrated that the combination of DCA and sulindac augments the selective killing of A549 and SCC25 cancer cells via ROS production, mitochondrial dysfunction, and apoptosis (30). Similarly, Florio et al., reported that the combination of three metabolic drugs, DCA, GW6471, and metformin resulted in a remarkable enhanced ROS production, modulated cell cycle progression, and promoted apoptosis in PGL cells (31). These findings are in line with the results reported in our study. In the present study, we found that DCA and 3Br-P together or in combined with 5-FU significantly reduced cell viability and proliferation of HT-29 cell lines (Fig. 8). Apoptosis plays an important role in treatment of cancer, as it is a popular target of many treatment strategies (32). Accordingly, we showed that the combined drug therapy, DCA + 3Br-P, promotes apoptosis more effectively than the single therapies in HT-29 cell lines (Fig. 3); a mechanism that may be induced by modulating pathways such as ROS-dependent apoptosis in HT-29 cell lines. In the mitochondrial (caspase-dependent intrinsic) pathway that induces apoptosis, caspases, in particular caspase-3, are crucial mediators for the apoptotic machinery in many cell types (33). This pathway is controlled by B-cell lymphoma-2 (BCL2) family proteins, composed of members that either promote or inhibit apoptosis. A major checkpoint in cellular fate is a balance formed between pro-apoptotic (Bax) and anti-apoptotic (Bcl-2) members (34). Increased Bax/Bcl-2 ratio up-regulates caspase-3, which leads to apoptosis of tumor cells (35). In the current study, we evaluated caspase 3 release, Bax/Bcl-2 ratio expression and mitochondrial membrane potential (ΔΨm). The results demonstrated that the three mentioned parameters increased by the combined drug therapy (DCA + 3Br-P) in comparison to single drug therapy. As a result, more studies are needed to investigate the mechanisms underlying the anticancer effect of combined 3Br-P + DCA and a combination of other mitocans treatment on CRC cells (Fig. 11).

We have indicated that a combination of 3Br-P + DCA exerts an antitumor effect in vitro by activation of mitochondria-dependent apoptosis. The first goal of target therapy is to fight cancer cells with more precision and fewer side effects potentially. Targeted cancer therapies were designed to target a specific molecule that is critical for the growth and expansion of cancer cell, hence, blocking these molecules can kill cancer cells without any harm to normal cells. According to the mitocans features, we can consider them as apoptosis inducers. However, the results of the combination of 3Br-P + DCA in this study have no significant difference with the 5-FU alone; however, we should never ignore the primary goal of this study to show that combination therapy has lower side effects and resistance to treatment.

CRC: colorectal cancer; 5-FU: 5-Fluorouracil; MTT: 3-4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide; qRT-PCR: quantitative real-time polymerase chain reaction; DCA : Dichloroacetate; 3Br-P: 3-bromopyruvate; VDAC: voltage-dependent anion channel; HT-29: Human colorectal adenocarcinoma; HEK-293: human embryonic kidney 293; SCT: sodium citrate

Acknowledgements

We are grateful to all persons contributing for promoting this investigation.

Authors’ contributions

M.M. and M.J.K. study concept and design, critical revision of the manuscript for important intellectual content; B.B. acquisition of data, analysis, and interpretation of data; S.A. and L.Z. statistical analysis; A.T. and H.N. administrative, technical, and material supports, drafting of the manuscript; The author(s) read and approved the final manuscript.

Funding

This study was financially supported by Cellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran (Grant number CMRC-9517).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The Authors declare that they have no competing interests

Author details

¹ Cellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. ² Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.³ Toxicology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. ⁴ Department of Toxicology, Faculty of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. ⁵ Department of Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. ⁶Department of Pharmacology, Faculty of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics. 2012;2(1):3.
Rasouli MA, Moradi G, Roshani D, Nikkhoo B, Ghaderi E, Ghaytasi B. Prognostic factors and survival of colorectal cancer in Kurdistan province, Iran: A population-based study (2009–2014). Medicine (Baltimore). 2017;96(6).
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422.
Nazim UMD, Rasheduzzaman M, Lee Y-J, Seol D-W, Park S-Y. Enhancement of TRAIL-induced apoptosis by 5-fluorouracil requires activating Bax and p53 pathways in TRAIL-resistant lung cancers. Oncotarget. 2017;8(11):18095.
O’Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994;331(8):502–7.
André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.
Oliveira PJ. Mitochondrial biology and experimental therapeutics. Springer; 2018.
Fereidoonnezhad M, Faghih Z, Mojaddami A, Sakhteman A, Rezaei Z. A comparative docking studies of dichloroacetate analogues on four isozymes of pyruvate dehydrogenase kinase in humans. dent. 2016;1(4):5.
Shoshan-Barmatz V, Krelin Y, Shteinfer-Kuzmine A, Arif T. Voltage-dependent anion channel 1 as an emerging drug target for novel anti-cancer therapeutics. Front Oncol. 2017;7:154.
Chen J-B, Chern T-R, Wei T-T, Chen C-C, Lin J-H, Fang J-M. Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment. J Med Chem. 2013;56(9):3645–55.
Chong D, Ma L, Liu F, Zhang Z, Zhao S, Huo Q, et al. Synergistic antitumor effect of 3-bromopyruvate and 5-fluorouracil against human colorectal cancer through cell cycle arrest and induction of apoptosis. Anticancer Drugs. 2017;28(8):831–40.
Tong J, Xie G, He J, Li J, Pan F, Liang H. Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer. Biomed Res Int. 2011;2011.
Ozkan A, Isgor SB, Sengul G, Isgor YG. Computer vision based automated cell counting pipeline: a case study for HL60 cancer cell on hemocytometer. 2018;
Rai Y, Pathak R, Kumari N, Sah DK, Pandey S, Kalra N, et al. Mitochondrial biogenesis and metabolic hyperactivation limits the application of MTT assay in the estimation of radiation induced growth inhibition. Sci Rep. 2018;8(1):1–15.
Yang Q, Zhou Y, Wang J, Fu W, Li X. Study on the mechanism of excessive apoptosis of nucleus pulposus cells induced by shRNA‐Piezo1 under abnormal mechanical stretch stress. J Cell Biochem. 2019;120(3):3989–97.
Szychowski KA, Wnuk A, Rzemieniec J, Kajta M, Leszczyńska T, Wójtowicz AK. Triclosan-evoked neurotoxicity involves NMDAR subunits with the specific role of GluN2A in caspase-3-dependent apoptosis. Mol Neurobiol. 2019;56(1):1–12.
Jiang W, Wang R, Liu D, Zuo M, Zhao C, Zhang T, et al. Protective effects of kaempferitrin on advanced glycation end products induce mesangial cell apoptosis and oxidative stress. Int J Mol Sci. 2018;19(11):3334.
Ma Y, Wang Q, Zhu Q, Liu M, Chen D, Han Z, et al. Dual fluorescence nanoconjugates for ratiometric detection of reactive oxygen species in inflammatory cells. J Biophotonics. 2018;11(2):e201700015.
Bernard S, Agustriawan D. Identification of microRNA Targeting Cancer Gene of Colorectal Carcinoma in Caucasian Population. In: 2019 International Conference on Information and Communications Technology (ICOIACT). IEEE; 2019. p. 423–7.
Huang C-Y, Ju D-T, Chang C-F, Reddy PM, Velmurugan BK. A review on the effects of current chemotherapy drugs and natural agents in treating non–small cell lung cancer. Biomedicine. 2017;7(4).
Jeffe DB, Pérez M, Cole EF, Liu Y, Schootman M. The effects of surgery type and chemotherapy on early-stage breast cancer patients’ quality of life over 2-year follow-up. Ann Surg Oncol. 2016;23(3):735–43.
Lee JJ, Beumer JH, Chu E. Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol. 2016;78(3):447–64.
Battogtokh G, Cho Y-Y, Lee JY, Lee HS, Kang HC. Mitochondrial-Targeting Anticancer Agent Conjugates and Nanocarrier Systems for Cancer Treatment. Front Pharmacol [Internet]. 2018;9:922. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30174604
He H, Li D-W, Yang L-Y, Fu L, Zhu X-J, Wong W-K, et al. A novel bifunctional mitochondria-targeted anticancer agent with high selectivity for cancer cells. Sci Rep. 2015;5:13543.
Ke X, Shen L. Molecular targeted therapy of cancer: The progress and future prospect. Front Lab Med. 2017;1(2):69–75.
Wang T-A, Zhang X-D, Guo X-Y, Xian S-L, Lu Y-F. 3-Bromopyruvate and sodium citrate target glycolysis, suppress survivin, and induce mitochondrial-mediated apoptosis in gastric cancer cells and inhibit gastric orthotopic transplantation tumor growth. Oncol Rep. 2016;35(3):1287–96.
Ihrlund LS, Hernlund E, Khan O, Shoshan MC. 3‐Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. Mol Oncol. 2008;2(1):94–101.
Chen Y, Wei L, Zhang X, Liu X, Chen Y, Zhang S, et al. 3‑Bromopyruvate sensitizes human breast cancer cells to TRAIL‑induced apoptosis via the phosphorylated AMPK‑mediated upregulation of DR5. Vol. 40. 2018.
Ayyanathan K, Kesaraju S, Dawson-Scully K, Weissbach H. Combination of sulindac and dichloroacetate kills cancer cells via oxidative damage. PLoS One [Internet]. 07/17. 2012;7(7):e39949–e39949. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22866174
Florio R, De Lellis L, Veschi S, Verginelli F, di Giacomo V, Gallorini M, et al. Effects of dichloroacetate as single agent or in combination with GW6471 and metformin in paraganglioma cells. Sci Rep. 2018;8(1):1–14.
Wong RSY. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30(1):87.
Nakajima Y, Kuranaga E. Caspase-dependent non-apoptotic processes in development. Cell Death Differ. 2017;24(8):1422–30.
Campbell KJ, Tait SWG. Targeting BCL-2 regulated apoptosis in cancer. Open Biol [Internet]. 2018;8(5):180002. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29769323
Pan Y, Ye C, Tian Q, Yan S, Zeng X, Xiao C, et al. miR-145 suppresses the proliferation, invasion and migration of NSCLC cells by regulating the BAX/BCL-2 ratio and the caspase-3 cascade. Oncol Lett. 2018;15(4):4337–43.

Due to technical limitations, table 1 is only available as a download in the Supplemental Files section.

No competing interests reported.

Download PDF

Journal Publication

published 07 Aug, 2021

Read the published version in BMC Cancer →

Editorial decision: Major revision
19 May, 2021
Reviews received at journal
29 Apr, 2021
Reviewers agreed at journal
24 Apr, 2021
Reviewers invited by journal
23 Apr, 2021
Editor assigned by journal
23 Apr, 2021
Editor invited by journal
23 Apr, 2021
Submission checks completed at journal
23 Apr, 2021
First submitted to journal
12 Apr, 2021

You are reading this latest preprint version

The Combined Effect of Dichloroacetate and 3-Bromopyruvate in Colorectal Cancer Cell Line, HT-29; The Mitochondrial Pathway Apoptosis

Status:

Journal Publication

Version 1

Abstract

Background

Methods

Results

Conclusion

Figures

Background

Methods

Results

Discussion

Conclusion

Abbreviations

Declarations

References

Tables

Additional Declarations

Supplementary Files

Status:

Journal Publication

Version 1